Blockchain Registration Transaction Record

Quantum BioPharma's Lucid-MS Takes Center Stage on BioMedWire Podcast

Quantum BioPharma (QNTM) discusses Lucid-MS for multiple sclerosis and unbuzzd(TM) alcohol metabolism product on BioMedWire Podcast. Phase 2 trial upcoming.

This news matters because Quantum BioPharma is tackling a critical unmet need in multiple sclerosis: mobility loss from nerve damage, which current treatments don't fully address. If Lucid-MS succeeds in Phase 2 trials, it could offer a new therapeutic option for millions of MS patients worldwide. Additionally, their commercial product unbuzzd(TM) provides a novel solution for alcohol metabolism, potentially reducing alcohol-related harm. For investors, the company's pipeline and royalty stream from unbuzzd(TM) sales represent multiple value drivers.